Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: A biphasic experimental study

Toxicology Letters

Volumn 219, Issue 2, 2013, Pages 178-193

  Chitra, Palanivel ^a   Saiprasad, Gowrikumar ^a   Manikandan, Ramar ^b   Sudhandiran, Ganapasam ^a  

^a UNIVERSITY OF MADRAS   (India)

^b ALAGAPPA UNIVERSITY   (India)

Author keywords

Berberine; Bleomycin; NF B; Oxidative stress; Pulmonary fibrosis; TGF 1

Indexed keywords

BERBERINE; BLEOMYCIN; COLLAGEN; HISTAMINE; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; HISTOPATHOLOGY; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; LUNG TOXICITY; MALE; MAST CELL; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; ANTIMETABOLITES; BERBERINE; BLEOMYCIN; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; COLLAGEN; HISTAMINE RELEASE; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; LUNG DISEASES; MALE; MALONDIALDEHYDE; MICROSCOPY, CONFOCAL; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; OXIDATIVE STRESS; PEROXIDASE; PULMONARY FIBROSIS; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

ANIMALIA; RATTUS NORVEGICUS;

EID: 84876300088     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.03.009     Document Type: Article

References (56)

1. Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., Izumi K., Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. American Journal of Respiratory and Critical Care Medicine 2005, 171(11):1279-1285.
2. Ashcroft T., Simpson J.M., Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of Clinical Pathology 1988, 41(4):467-470.
3. Bargagli E., Olivieri C., Bennett D., Prasse Muller-Quernheim A., Rottoli P. Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respiratory Medicine 2009, 103:1245-1256.
4. Bayfield R.F., Cole E.R. Colorimetric estimation of vitamin A with trichloroacetic acid. Methods in Enzymology 1980, 67:189-203.
5. Beauchamp C., Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Analytical Biochemistry 1971, 44(1):276-287.
6. Bieri J.G., Teets L., Belavculy B., Andrews E.L. Serum vitamin E levels in a normal adult population in the Washington DC area. Proceedings of the Society for Experimental Biology and Medicine 1964, 117:131-133.
7. Cederbaum A.I., Cohen G. Microsomal oxidant radical production and ethanol oxidation. Methods in Enzymology 1984, 105:516-522.
8. Chaudhary N.I., Schnapp A., Park J.E. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. American Journal of Respiratory and Critical Care Medicine 2006, 173:769-776.
9. Chen Y., Chen J., Dong J., Liu W. Antifibrotic effect of interferon gamma in silicosis model of rat. Toxicology Letters 2005, 155:353-360.
10. Cho H.Y., Reddy S.P., Yamamoto M., Kleeberger S.R. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB Journal 2004, 18(11):1258-1260.
11. Claiborne A. Catalase activity. Handbook of Methods of Oxygen Free Radicals Research 1985, 283-284. CRC Press, Boca Raton, FL. R.A. Greenwald (Ed.).
12. Cortijo J., Cerdá-Nicolás M., Serrano A., Bioque G., Estrela J.M., Santangelo F., Esteras A., Llombart-Bosch A., Morcillo E.J. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. European Respiratory Journal 2001, 17(6):1228-1235.
13. Daba M.H., El-Tahir K.E., Al-Arifi M.N., Gubara O.A. Drug-induced pulmonary fibrosis. Saudi Medical Journal 2004, 25:700-706.
14. Daniil Z.D., Papageorgiou E., Koutsokera A., Kostikas K., Kiropoulos T., Papaioannou A.L., Gourgoulianis K.I. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics 2008, 21:26-31.
15. Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. American Journal of Respiratory and Critical Care Medicine 2000, 161(4):1172-1178.
16. Edwards C.A., Brien J.R. Modified assay for determination of Hydroxyproline in tissue hydrolyzate. Clinica Chimica Acta 1980, 104:161-167.
17. Giri S.N., Biring I., Nguyen T., Wang Q., Hyde D.M. Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice. Nitric Oxide 2002, 7:109-118.
18. Green F.H.Y. Overview of pulmonary fibrosis. Chest 2002, 122(6):334-339.
19. Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. New England Journal of Medicine 2001, 345:517-525.
20. Hobbs A.J., Higgs A., Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annual Review of Pharmacology and Toxicology 1999, 39:191-220.
21. Hunninghake G.W., Kalica A.R. Approaches to the treatment of pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 1995, 151:915-918.
22. Izbicki G., Segel M.J., Christensen T.G., Conner M.W., Breuer R. Time course of bleomycin-induced lung fibrosis. International Journal of Experimental Pathology 2002, 83(3):111-119.
23. Kang E.S., Woo I.S., Kim H.J., Eun S.Y., Paek K.S., Kim H.J., Chang K.C., Lee J.H., Lee H.T., Kim J.H., Nishinaka T., Yabe-Nishimura C., Seo H.G. Up-regulation of aldose reductase expression mediated by phosphatidyl inositol3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radical Biology and Medicine 2007, 43(4):535-545.
24. Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., Sheppard D., Chapman H.A. Alveolar epithelial cell mesenchymal transition develops invivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proceedings of the National Academy of Sciences of United States of America 2006, 103(35):13180-13185.
25. Lo A.H., Liang Y.C., Lin-Shiau S.Y., Ho C.T., Lin J.K. Carnosol, an antioxidant in rosemary, suppresses inducible nitric oxide synthase through down regulating nuclear factor-kappa B in mouse macrophages. Carcinogenesis 2002, 23:983-991.
26. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin-phenol reagent. Journal of Biological Chemistry 1951, 193:265-275.
27. Miranda K.M., Espey M.G., Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001, 5(1):62-71.
28. Moeller A., Ask K., Warburton D., Gauldie J., Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. International Journal of Biochemistry and Cell Biology 2008, 40:362-382.
29. Molina M., Serran M.A., Bulbena O., Fernandez Z.L., Closa D., Marin A.A., Torrego A., Mullol J., Picado C., Xaubet A. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax 2006, 61(7):604-610.
30. Moran M.S., Depierre J.W., Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochimica et Biophysica Acta 1979, 582(1):67-78.
31. Nichans W.G., Samuelson D. Formation of malondialdehyde from phospholipid arachidonate during microsomal lipid peroxidation. European Journal of Biochemistry 1968, 6:126-130.
32. Ota K. Diagnosis and treatment of idiopathic pulmonary fibrosis. Nippon Naika Gakkai Zasshi - Journal of Japanese Society of Internal Medicine 2007, 96(3):557-561.
33. Ou X., Feng Y., Wen F., Huang X., Xiao J., Wang K., Wang T. Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice. Chinese Medical Journal 2008, 121(18):1821-1829.
34. Pesci A., Bertorelli G., Gabrielli M., Olivieri D. Mast cells in fibrotic disorders. Chest 1993, 103:989-996.
35. Piguet P.F., Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. European Respiratory Journal 1994, 7(3):515-518.
36. Rahman I., Skwarska E., Henry M., Davis M., O'Connor C.M., FitzGerald M.X., Greening A., MacNee W. Systemic and pulmonary oxidative stress in IPF. Free Radical Biology and Medicine 1999, 27(1/2):60-68.
37. Ranieri G., Labriola A., Achille G., Florio G., Zito A.F., Grammatica L., Paradiso A. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. International Journal of Oncology 2002, 21(6):1317-1323.
38. Razonable R.R., Henault M., Lee L.N., Laethem C., Johnston P.A., Watson H.L., Paya C.V. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrobial Agents and Chemotherapy 2005, 49(4):1617-1621.
39. Saravanan R., Jae W.H., Hongwei Y., Nandini K., Irfan R. Anti-inflammatory effect of a selective IκB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke. Pulmonary Pharmacology and Therapeutics 2010, 23(3):172-181.
40. Schwartz D.A., Helmers R.A., Galvin J.R., Van Fossen D.S., Frees K.L., Dayton C.S., Burmeister L.F., Hunninghake G.W. Determinants of survival in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 1994, 149:450-454.
41. Sharma N., Trikha P., Athar M., Raisuddin S. Inhibition of benzo[a]pyrene and cyclophosphamide induced mutagenicity by cinnamomum cassia. Mutation Research 2001, 480/481:179-188.
42. Shimizu Y., Dobaski K., Iizuka K., Horie T., Suzuki K., Tukagoshi H., Nakazawa T., Nakazato Y., Moro M. Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. American Journal of Respiratory and Critical Care Medicine 2001, 163:210-217.
43. Shishodia S., Potdar P., Gairola C.G., Agarwal B.B. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kB activation through inhibition of IkB a kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclinD1. Carcinogenesis 2003, 24(7):1269-1279.
44. Shore P.A. Fluorimetric assay of histamine. Methods in Enzymology 1971, 17:842-845.
45. Sriram N., Kalayarasan S., Sudhandiran G. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulmonary Pharmacology & Therapeutics 2009, 22:221-236.
46. Sullivan M.X., Clarke H.C.N. A highly specific procedure for ascorbic acid. Journal of the Association of Official Analytical Chemists 1955, 38:514.
47. Sun X., Zhang X., Hu H., Lu Y., Chen J., Yasuda K., Wang H. Berberine inhibits hepatic stellate cell proliferation and prevents experimental liver fibrosis. Biological and Pharmaceutical Bulletin 2009, 32(9):1533-1537.
48. Tabata C., Tabata R., Kadokawa Y., Hisamori S., Takahashi M., Mishima M., Nakano T., Kub H. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. Journal of Immunology 2007, 179:708-714.
49. Tomioka M., Goto T., Lee D.G., Bienenstock J., Befus D. Isolation and characterization of lung mast cells from rats with bleomycin-induced pulmonary fibrosis. Immunology 1989, 66:439-444.
50. Venkatesan N., Pini L., Ludwig M.S. Changes in Smad expression and subcellular localization in bleomycin-induced pulmonary fibrosis. American Journal of Physiology. Lung Cellular and Molecular Physiology 2004, 287:1342-1347.
51. Vuddanda P.R., Chakraborty S., Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opinion on Investigational Drugs 2010, 19:1297-1307.
52. Wei H., Frenkel K. Relationship of oxidative events and DNA oxidation in SENCAR mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 1993, 14(6):1195-1201.
53. Yara S., Kawakami K., Kudeken N., Tohyama M., Teruya K., Chinen T., Awaya A., Saito A. FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clinical and Experimental Immunology 2001, 124:77-85.
54. Zhang X.Y., Shimura S., Masuda T., Saitoh H., Shirato K. Antisense oligonucleotides to NF-kappa B improve survival in bleomycin-induced pneumopathy of the mouse. American Journal of Respiratory and Critical Care Medicine 2000, 162(4):1561-1568.
55. Zhoua X.M., Huanga M.M., Heb C.C., Li J.X. Inhibitory effects of citrus extracts on the experimental pulmonary fibrosis. Journal of Ethnopharmacology 2009, 126:143-148.
56. Zuo F., Kaminski N., Eugui E., Allard J., Yakhini Z., Ben-Dor A., Lollini L., Morris D., Kim Y., DeLustro B., Sheppard D., Pardo A., Selman M., Heller R.A. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proceedings of the National Academy of Sciences of United States of America 2002, 99(9):6292-6297.